Modelling the Impact of Artemisinin Combination Therapy and Long-Acting Treatments on Malaria Transmission Intensity
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Artemisinin derivatives used in recently introduced combination therapies (ACTs) for Plasmodium falciparum malaria significantly lower patient infectiousness and have the potential to reduce population-level transmission of the parasite. With the increased interest in malaria elimination, understanding the impact on transmission of ACT and other antimalarial drugs with different pharmacodynamics becomes a key issue. This study estimates the reduction in transmission that may be achieved by introducing different types of treatment for symptomatic P. falciparum malaria in endemic areas. METHODS AND FINDINGS: We developed a mathematical model to predict the potential impact on transmission outcomes of introducing ACT as first-line treatment for uncomplicated malaria in six areas of varying transmission intensity in Tanzania. We also estimated the impact that could be achieved by antimalarials with different efficacy, prophylactic time, and gametocytocidal effects. Rates of treatment, asymptomatic infection, and symptomatic infection in the six study areas were estimated using the model together with data from a cross-sectional survey of 5,667 individuals conducted prior to policy change from sulfadoxine-pyrimethamine to ACT. The effects of ACT and other drug types on gametocytaemia and infectiousness to mosquitoes were independently estimated from clinical trial data. Predicted percentage reductions in prevalence of infection and incidence of clinical episodes achieved by ACT were highest in the areas with low initial transmission. A 53% reduction in prevalence of infection was seen if 100% of current treatment was switched to ACT in the area where baseline slide-prevalence of parasitaemia was lowest (3.7%), compared to an 11% reduction in the highest-transmission setting (baseline slide prevalence = 57.1%). Estimated percentage reductions in incidence of clinical episodes were similar. The absolute size of the public health impact, however, was greater in the highest-transmission area, with 54 clinical episodes per 100 persons per year averted compared to five per 100 persons per year in the lowest-transmission area. High coverage was important. Reducing presumptive treatment through improved diagnosis substantially reduced the number of treatment courses required per clinical episode averted in the lower-transmission settings although there was some loss of overall impact on transmission. An efficacious antimalarial regimen with no specific gametocytocidal properties but a long prophylactic time was estimated to be more effective at reducing transmission than a short-acting ACT in the highest-transmission setting. CONCLUSIONS: Our results suggest that ACTs have the potential for transmission reductions approaching those achieved by insecticide-treated nets in lower-transmission settings. ACT partner drugs and nonartemisinin regimens with longer prophylactic times could result in a larger impact in higher-transmission settings, although their long term benefit must be evaluated in relation to the risk of development of parasite resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Woolhouse, M. E. J., Dye, C., Etard, J.-F., Smith, T., Charlwood, J. D., Garnett, G. P., Hagan, P., Hii, J. L. K., Ndhlovu, P. D., Quinnell, R. J., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.338 · Cited by 1,194
Bhattarai, A., Ali, A. S., Kachur, S. P., Mårtensson, A., Abbas, A. K., Khatib, R., Al-mafazy, A.-W., Ramsan, M., Rotllant, G., Gerstenmaier, J. F., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040309 · Cited by 647 · cited 4×
“Since then, data from a number of settings including Zanzibar [14] and Rwanda have demonstrated a significant reduction in malaria cases following ACT introduction.”
BackgroundInfluentialThe entomological inoculation rate and Plasmodium falciparum infection in African children
Smith, D. L., Dushoff, J., Snow, R. W., & Hay, S. I. (2005) · Nature · doi:10.1038/nature04024 · Cited by 369 · cited 1×
“A similar pattern is observed with other malaria control interventions [43] because of the nonlinear relationship between prevalence and incidence of malaria infection [44].”
ResultHay, S. I., Rogers, D. J., Toomer, J. F., & Snow, R. W. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90246-3 · Cited by 312
A new global malaria eradication strategy
Feachem, R., & Sabot, O. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60424-9 · Cited by 183 · cited 1×
“With the renewed interest in minimising transmission and moving toward malaria elimination [8], it is increasingly important to evaluate the ability of antimalarial treatments not only to cure disease, but also to reduce transmission.”
BackgroundCarrara, V. I., Sirilak, S., Thonglairuam, J., Rojanawatsirivet, C., Proux, S., Gilbos, V., Brockman, A., Ashley, E. A., McGready, R., Krudsood, S., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030183 · Cited by 146
How do patients use antimalarial drugs? A review of the evidence
Yeung, S., & White, N. J. (2005) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2004.01364.x · Cited by 124 · cited 1×
“Our analysis deliberately represents an ideal scenario in order to estimate the maximum potential for ACT impact, whilst in reality the difficulties of imperfect patient adherence and of achieving good coverage in all health sectors [1,46] would reduce the speed and magnitude of transmission reductions, potentially su…”
Cited by
A new world malaria map: Plasmodium falciparum endemicity in 2010
Gething, P. W., Patil, A. P., Smith, D. L., Guerra, C. A., Elyazar, I. R., Johnston, G. L., Tatem, A. J., & Hay, S. I. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-378 · Cited by 1,146
Bousema, T., & Drakeley, C. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-10 · Cited by 746
Self-citationArtemisinin resistance: current status and scenarios for containment
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P. J., Socheat, D., & von Seidlein, L. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2331 · Cited by 645
Griffin, J. T., Hollingsworth, T. D., Okell, L. C., Churcher, T. S., White, M., Hinsley, W., Bousema, T., Drakeley, C. J., Ferguson, N. M., Basáñez, M.-G., et al. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000324 · Cited by 595
“These include new LLINs, which have increased killing effects on the vectors compared to traditional nets and are more durable [21–25], and ACTs, which, through their gametocytocidal effect, can impact transmission from humans to vectors [26,27].”
BackgroundSelf-citationA Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010
Gething, P. W., Elyazar, I. R. F., Moyes, C. L., Smith, D. L., Battle, K. E., Guerra, C. A., Patil, A. P., Tatem, A. J., Howes, R. E., Myers, M. F., et al. (2012) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001814 · Cited by 538
Metadata
- Authors
- Okell, L. C., Drakeley, C. J., Bousema, T., Whitty, C. J. M., & Ghani, A. C.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-11-25
- Volume
- 5
- Issue
- 11
- Pages
- e226
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2052028492
- Cited by
- 146
- References
- 8
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.